This, to our knowledge, is the first study to examine the effects of GPP in NASH, suggesting that the mechanism might be preliminarily initiated by the modulation of the gut microbiota and TLR2/NLRP3 pathway. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.